CJC-1295 with DAC Research Guide: Drug Affinity Complex Technology & Sustained GH Elevation

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is CJC-1295 with DAC?

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that incorporates a Drug Affinity Complex (DAC) — a proprietary bioconjugation technology that dramatically extends its biological half-life. While native GHRH (1-44) has a plasma half-life of less than 10 minutes due to rapid enzymatic degradation, CJC-1295 with DAC achieves a half-life of approximately 6-8 days, representing one of the most significant pharmacokinetic modifications in peptide research.

The compound was originally developed by ConjuChem Biotechnologies (now ConjuChem LLC) as a potential treatment for growth hormone deficiency. It consists of a modified GHRH (1-29) fragment — the minimum sequence required for full biological activity at the GHRH receptor — with two critical modifications: a D-alanine substitution at position 2 to resist dipeptidyl peptidase IV (DPP-IV) cleavage, and a reactive maleimido-propionamide (MPA) group at the C-terminus that enables covalent binding to circulating serum albumin after subcutaneous injection.

This albumin bioconjugation is the essence of the DAC technology. Rather than circulating freely and being rapidly cleared by the kidneys, the CJC-1295 molecule anchors itself to albumin — the most abundant protein in human blood, with its own half-life of approximately 19 days. This “hitchhiking” strategy allows the peptide to remain bioactive in circulation for days rather than minutes, fundamentally changing its pharmacodynamic profile.

The Drug Affinity Complex: How Bioconjugation Works

Understanding the DAC technology requires a closer look at the molecular engineering involved. The concept was pioneered by ConjuChem and described in foundational work by Bhatt et al. (2003) and subsequently in the Alba et al. (2006) study that first characterized the compound in animal models.

The Maleimide-Thiol Reaction

The key to DAC technology is the maleimido-propionamide (MPA) linker attached to the lysine residue at position 40 of the modified peptide. After subcutaneous injection, this maleimide group undergoes a highly specific Michael addition reaction with the free sulfhydryl group (thiol, -SH) on Cysteine-34 of human serum albumin. This covalent bond is essentially irreversible under physiological conditions.

The reaction is remarkably selective. Despite the presence of numerous proteins in plasma, the maleimide group preferentially reacts with albumin’s Cys-34 because:

• Albumin is present at extremely high concentrations (~40 g/L in plasma)
• Cys-34 is the only free thiol on the albumin molecule (not involved in disulfide bonds)
• The reaction kinetics favor the abundant, accessible albumin thiol over other potential targets

Pharmacokinetic Consequences

Once conjugated to albumin, CJC-1295 inherits many of albumin’s pharmacokinetic properties. Albumin is protected from renal clearance by the neonatal Fc receptor (FcRn), which recycles it back into circulation after endocytosis. This FcRn-mediated recycling pathway extends the effective circulation time of anything bound to albumin.

The practical result is striking: where unmodified GHRH (1-29) is cleared within minutes, CJC-1295 with DAC maintains measurable bioactivity for nearly a week after a single injection. This transforms the peptide from a compound requiring multiple daily administrations to one that could theoretically be administered once or twice weekly.

Comparison to Other Half-Life Extension Technologies

The DAC approach is not the only strategy for extending peptide half-life, but it has unique characteristics:

Technology	Mechanism	Half-Life Extension	Example
PEGylation	Polyethylene glycol attachment	Hours to days	PEG-MGF
Fc Fusion	Antibody Fc region fusion	Days to weeks	Dulaglutide
Albumin Binding (non-covalent)	Fatty acid linker	Hours to days	Semaglutide
DAC (covalent albumin conjugation)	Maleimide-thiol bond	~6-8 days	CJC-1295 with DAC
D-amino acid substitution	Protease resistance	Minutes to hours	CJC-1295 no DAC

The covalent nature of DAC binding distinguishes it from the non-covalent albumin binding used by drugs like semaglutide (which employs a fatty acid side chain that associates with albumin through hydrophobic interactions). Covalent binding is more permanent and results in longer-lasting effects, though it also means the compound cannot dissociate from albumin to interact with receptors as freely.

The Foundational Clinical Evidence: Teichman et al. (2006)

The pivotal human study on CJC-1295 with DAC was published by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism in 2006. This dose-escalation study in healthy adult volunteers established the core pharmacokinetic and pharmacodynamic profile that has informed all subsequent CJC-1295 research.

Study Design

The study enrolled healthy adults aged 21-61 years who received single subcutaneous injections of CJC-1295 at doses ranging from 30 to 300 mcg/kg. Growth hormone and IGF-1 levels were monitored for up to 28 days post-injection.

Key Findings

The results were remarkably consistent and dose-dependent:

• GH elevation: Mean plasma GH concentrations increased 2- to 10-fold above baseline, persisting for 6 days or more after a single injection
• IGF-1 elevation: Mean plasma IGF-1 concentrations increased 1.5- to 3-fold, persisting for 9-11 days
• Half-life: The estimated terminal half-life was 5.8-8.1 days
• Dose proportionality: Both the magnitude and duration of GH/IGF-1 elevation were dose-dependent
• Tolerability: The compound was described as “safe and relatively well tolerated” at the tested doses

The duration of IGF-1 elevation exceeding that of GH elevation is expected pharmacologically — IGF-1 is produced downstream of GH signaling (primarily by the liver) and has its own independent half-life dynamics.

Pulsatile GH Secretion Is Preserved

One of the most significant findings from the follow-up study (also involving Teichman’s group) was that CJC-1295 preserved the natural pulsatile pattern of GH secretion. Unlike exogenous GH administration, which produces non-physiological flat-line GH levels, CJC-1295 increased trough GH levels and amplified the naturally occurring GH pulses while maintaining the pulsatile architecture.

This is physiologically important because GH pulsatility is thought to be critical for many of GH’s downstream effects. The hypothalamic-pituitary feedback loop remains intact with GHRH analogs — somatostatin still suppresses GH release periodically, creating the normal peaks and troughs that continuous exogenous GH cannot replicate.

CJC-1295 with DAC vs. CJC-1295 without DAC (Modified GRF 1-29)

One of the most common points of confusion in peptide research is the difference between CJC-1295 with DAC and CJC-1295 without DAC (sometimes called Modified GRF 1-29, Mod GRF, or CJC-1295 no DAC). While they share the same core peptide sequence, their pharmacokinetic profiles are fundamentally different.

Key Differences

Parameter	CJC-1295 with DAC	CJC-1295 No DAC (Mod GRF 1-29)
Half-life	~6-8 days	~30 minutes
Albumin binding	Covalent (irreversible)	None
GH elevation pattern	Sustained, elevated baseline	Acute pulse, then return to baseline
Administration frequency	1-2x per week in research protocols	2-3x daily in research protocols
IGF-1 elevation	Sustained for 9-11 days	Brief, returns to baseline within hours
GH pulsatility	Preserved but with elevated trough	Creates acute pulse, natural rhythm maintained
GH bleed effect	Some continuous low-level elevation	Minimal — more discrete pulses

The “GH Bleed” Debate

The extended half-life of CJC-1295 with DAC creates what researchers sometimes call “GH bleed” — a sustained low-level elevation of GH between the amplified pulses. Whether this continuous low-level elevation produces different physiological effects compared to the purely pulsatile pattern produced by the no-DAC version is an active area of discussion in research literature.

Some researchers hypothesize that the constant GHRH receptor stimulation from the DAC version could lead to receptor desensitization over time, potentially blunting the GH response with chronic administration. Others argue that the clinical data from the Teichman study showed maintained efficacy across the study period without evidence of tachyphylaxis.

For a detailed comparison of the non-DAC version, see our guide: CJC-1295/Ipamorelin Combination Research Guide.

The GH/IGF-1 Axis: Context for CJC-1295 Research

To fully appreciate CJC-1295 research, it’s essential to understand the growth hormone axis — one of the most studied endocrine systems in biomedical research.

The Hypothalamic-Pituitary-Somatotroph Axis

Growth hormone secretion is regulated by a complex interplay of stimulatory and inhibitory signals:

1. GHRH (stimulatory): Released from the arcuate nucleus of the hypothalamus, binds GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and secretion
2. Somatostatin (inhibitory): Released from the periventricular nucleus, suppresses GH release and creates the troughs between pulses
3. Ghrelin/GHS (stimulatory): Acts on a separate receptor (GHS-R1a) to stimulate GH release — this is the pathway that GHRP-6, GHRP-2, Hexarelin, and Ipamorelin activate
4. IGF-1 (negative feedback): Circulating IGF-1 feeds back to both the hypothalamus and pituitary to suppress further GH release

CJC-1295 with DAC acts specifically at step 1 — it is a GHRH receptor agonist. This distinguishes it from growth hormone secretagogues (GHS) like Ipamorelin or GHRP-2, which act at step 3 through the ghrelin receptor.

Age-Related GH Decline (Somatopause)

One of the primary research interests in GHRH analogs like CJC-1295 relates to the age-related decline in GH secretion, sometimes called “somatopause.” GH secretion peaks during adolescence and then declines progressively — by age 60, most individuals produce significantly less GH than they did at age 20. A comprehensive review by Junnila et al. (2013) in Nature Reviews Endocrinology detailed the complex relationship between the GH/IGF-1 axis, aging, and longevity.

The decline in GH is accompanied by parallel reductions in IGF-1 and is associated (though causation remains debated) with age-related changes in body composition, bone density, muscle mass, and metabolic function. This association has driven decades of research into whether restoring youthful GH/IGF-1 levels could counteract some aspects of aging.

Serum Protein Profile Changes

Research published by Sackmann-Sala et al. (2009) examined how CJC-1295 activation of the GH/IGF-1 axis influenced the broader serum proteome. Using two-dimensional gel electrophoresis, the investigators identified significant changes in serum protein profiles following CJC-1295 administration in healthy adults.

The study identified alterations in proteins involved in:

• Lipid metabolism and transport
• Immune function
• Coagulation pathways
• Oxidative stress response

These findings suggested that sustained GH/IGF-1 elevation produces systemic proteomic changes beyond the direct somatotroph effects, indicating broader metabolic implications of prolonged GHRH receptor activation.

The Synergy Question: GHRH + GHRP Combinations

One of the most discussed topics in peptide research is the potential synergy between GHRH analogs (like CJC-1295) and growth hormone releasing peptides (GHRPs) that act through the ghrelin receptor. The rationale is straightforward: activating both the GHRH and ghrelin pathways simultaneously should produce greater GH release than either alone.

Early research by Bowers et al. (1990) established that GHRH and GHRPs act synergistically — the combination produces GH release that exceeds the sum of individual responses. This synergistic effect is thought to occur because the two pathways use different intracellular signaling mechanisms (cAMP/PKA for GHRH vs. IP3/PKC for GHRPs) that converge to amplify GH secretion.

The most commonly researched combination involves pairing a GHRH analog with Ipamorelin, a selective GHRP that activates the ghrelin receptor without significantly affecting cortisol, prolactin, or appetite. The theoretical advantage of this combination is maximum GH stimulation with minimal side effects.

However, it’s worth noting that the synergy data was established using short-acting GHRH and GHRPs. Whether the same synergistic relationship holds when using the long-acting DAC version of CJC-1295 (which provides continuous GHRH receptor stimulation) remains an area of ongoing investigation.

Research Applications and Areas of Investigation

CJC-1295 with DAC has been investigated across several research domains, though it’s important to note that most evidence remains preclinical or from early-phase studies:

Body Composition Research

Given the well-established role of GH in regulating body composition, CJC-1295’s ability to sustain elevated GH/IGF-1 has made it a subject of body composition studies. The GH axis influences fat metabolism (promoting lipolysis), protein synthesis, and muscle maintenance. Sustained GH elevation, as produced by CJC-1295, provides a research model for studying these effects over extended periods.

Bone Metabolism

IGF-1 is a critical mediator of bone formation and maintenance. The sustained IGF-1 elevation produced by CJC-1295 (lasting 9-11 days per Teichman et al.) creates a research model for studying IGF-1’s role in osteoblast activity and bone mineral density.

Sleep Architecture

GH secretion is closely linked to sleep — the largest GH pulse of the day typically occurs during slow-wave sleep. Research on GHRH analogs has explored their effects on sleep architecture, including potential enhancement of slow-wave sleep duration and quality.

Wound Healing and Recovery

GH and IGF-1 are involved in tissue repair pathways. The sustained elevation of both hormones produced by CJC-1295 has been investigated in the context of recovery and tissue regeneration research, though published data in this specific area remains limited.

Safety Profile from Clinical Research

Based on the published clinical data (primarily from the Teichman et al. study and related ConjuChem-sponsored trials), the reported adverse effects of CJC-1295 with DAC were generally mild:

• Injection site reactions (redness, swelling)
• Transient flushing
• Headache
• Diarrhea (at higher doses)
• Transient increases in fasting glucose (expected with GH elevation)

The compound’s development program was discontinued not due to safety concerns in the clinical population, but for commercial and strategic reasons. However, the absence of long-term safety data (beyond the relatively short study periods) means that the full safety profile remains incompletely characterized.

Practical Research Considerations

Stability and Storage

CJC-1295 with DAC, like most synthetic peptides, requires proper storage to maintain stability:

• Lyophilized (powder) form: stable at -20°C for extended periods; room temperature stability limited
• Reconstituted: should be refrigerated (2-8°C) and used within recommended timeframes
• Protect from light and avoid repeated freeze-thaw cycles
• The DAC moiety does not significantly alter storage requirements compared to other research peptides

Reconstitution

Standard reconstitution uses bacteriostatic water or sterile water. The peptide is highly soluble and typically reconstitutes readily. Researchers should handle reconstituted CJC-1295 with the same aseptic techniques used for any injectable research preparation.

Analytical Verification

When sourcing CJC-1295 with DAC for research, verify identity and purity through:

• HPLC purity analysis (expect ≥98% for research grade)
• Mass spectrometry for molecular weight confirmation
• Endotoxin testing if intended for cell culture or in vivo research

NorthPeptide provides third-party tested CJC-1295 with DAC for research applications. View product details and Certificate of Analysis.

Comparison with Other GHRH Analogs

CJC-1295 with DAC exists within a broader landscape of GHRH analog research. Understanding where it fits provides important context:

Compound	Type	Half-Life	Key Characteristic
GHRH (1-44)	Native hormone	~7 minutes	Endogenous, rapidly degraded
GHRH (1-29)	Truncated native	~10 minutes	Minimum active fragment
Sermorelin	GRF (1-29) NH2	~10-20 minutes	FDA-approved (diagnostic), widely studied
Modified GRF (1-29) / CJC-1295 no DAC	Modified GHRH	~30 minutes	DPP-IV resistant, no albumin binding
CJC-1295 with DAC	Albumin-conjugating GHRH	~6-8 days	Covalent albumin binding, sustained release
Tesamorelin	GHRH analog	~26-38 minutes	FDA-approved for HIV lipodystrophy

For detailed guides on related compounds, see our research articles on Sermorelin and Tesamorelin.

Current Research Landscape and Future Directions

While CJC-1295’s original clinical development was discontinued, the compound continues to be an important tool in several research areas:

• Peptide half-life extension technology: The DAC concept has influenced the development of other long-acting peptide therapeutics
• GH axis physiology: CJC-1295 remains a valuable tool for studying sustained GHRH receptor activation
• Bioconjugation chemistry: The maleimide-albumin conjugation strategy has been adapted for other therapeutic compounds
• Combination protocol research: Studies examining GHRH + GHRP synergy continue to use CJC-1295 as the GHRH component

The recent regulatory developments around peptide compounding (including the potential Category 2 reclassification) may also influence the research trajectory of CJC-1295 and related GHRH analogs.

Summary of Key Research References

Study	Year	Type	Focus	Reference
Teichman et al.	2006	Clinical Trial	CJC-1295 prolonged GH/IGF-1 elevation in healthy adults	PMID 16352683
Ionescu & Bhatt (Alba et al.)	2006	Preclinical	CJC-1295 normalizes growth in GHRH knockout mouse	PMID 16822960
Jetté et al.	2005	Preclinical	hGRF-albumin bioconjugates — identification of CJC-1295	PMID 15817669
Ionescu & Bhatt	2007	Clinical	Pulsatile GH secretion persists during CJC-1295 stimulation	PMID 17018654
Sackmann-Sala et al.	2009	Clinical/Proteomic	Serum protein profile changes from CJC-1295 GH/IGF-1 activation	PMC2787983
Junnila et al.	2013	Review	The GH/IGF-1 axis in ageing and longevity	PMC4074016
Ghigo et al.	1997	Review	GHRH and GH-releasing peptides: clinical and basic aspects	PMC5392015
Sigalos & Pastuszak	2018	Review	Safety and efficacy of growth hormone secretagogues	PMC5632578

---

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research. It does not constitute medical advice, treatment recommendations, or an endorsement for any therapeutic purpose. The research discussed herein is predominantly preclinical, and results may not translate to human outcomes. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving these compounds.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes.